Effects of age and sex on the pharmacokinetics of LCZ696, an angiotensin receptor neprilysin inhibitor

Journal of Clinical Pharmacology

Volumn 56, Issue 1, 2016, Pages 78-86

  Gan, Lu ^a   Langenickel, Thomas ^b   Petruck, Jesika ^a   Kode, Kiran ^c   Rajman, Iris ^b   Chandra, Priya ^b   Zhou, Wei ^b   Rebello, Sam ^b   Sunkara, Gangadhar ^b  

^a NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

^b NOVARTIS PHARMA AG   (Switzerland)

^c Novartis Healthcare Pvt Ltd   (India)

Author keywords

age; angiotensin receptor neprilysin inhibitor; LCZ696; pharmacokinetics; sex

Indexed keywords

3 (1 BIPHENYL 4 YLMETHYL 3 CARBOXY 1 BUTYLCARBAMOYL)PROPIONIC ACID; ALANINE AMINOTRANSFERASE; CREATININE; GAMMA GLUTAMYLTRANSFERASE; SACUBITRIL PLUS VALSARTAN; VALSARTAN; AMINOBUTYRIC ACID DERIVATIVE; ANGIOTENSIN RECEPTOR ANTAGONIST; BIPHENYL DERIVATIVE; MEMBRANE METALLOENDOPEPTIDASE; TETRAZOLE DERIVATIVE;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DIZZINESS; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; DYSURIA; FATIGUE; FEMALE; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; HEADACHE; HEART PALPITATION; HUMAN; MALE; MAXIMUM PLASMA CONCENTRATION; OPEN STUDY; PHARMACOKINETIC PARAMETERS; PLASMA CONCENTRATION-TIME CURVE; PRURITUS; RASH; SINGLE DRUG DOSE; TENSION HEADACHE; TIME TO MAXIMUM PLASMA CONCENTRATION; ADOLESCENT; AGE; ANTAGONISTS AND INHIBITORS; BLOOD; CLINICAL TRIAL; MIDDLE AGED; SEX DIFFERENCE; YOUNG ADULT;

ADOLESCENT; ADULT; AGE FACTORS; AGED; AMINOBUTYRATES; ANGIOTENSIN RECEPTOR ANTAGONISTS; BIPHENYL COMPOUNDS; FEMALE; HUMANS; MALE; MIDDLE AGED; NEPRILYSIN; SEX FACTORS; TETRAZOLES; VALSARTAN; YOUNG ADULT;

EID: 84954385143     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1002/jcph.571     Document Type: Article

References (27)

1. Feng LL, Karpinski PH, Sutton P, et al., LCZ696: a dual-acting sodium supramolecular complex. Tetrahedron Lett. 2012; 53 (3): 275-276
2. Gu J, Noe A, Chandra P, et al., Pharmacokinetics and pharmacodynamics of LCZ696, a novel dual-acting angiotensin receptor-neprilysin inhibitor (ARNi). J Clin Pharmacol. 2010; 50 (4): 401-414
3. Ksander GM, Ghai RD, deJesus R, et al., Dicarboxylic acid dipeptide neutral endopeptidase inhibitors. J Med Chem. 1995; 38 (10): 1689-1700
4. Mangiafico S, Costello-Boerrigter LC, Andersen IA, Cataliotti A, Burnett JC Jr., Neutral endopeptidase inhibition and the natriuretic peptide system: an evolving strategy in cardiovascular therapeutics. Eur Heart J. 2013; 34 (12): 886-893c
5. Segura J, Salazar J, Ruilope LM., Dual neurohormonal intervention in CV disease: angiotensin receptor and Neprilysin inhibition. Expert Opin Investig Drugs. 2013; 22 (7): 915-925
6. Gwathmey TM, Alzayadneh EM, Pendergrass KD, Chappell MC., Novel roles of nuclear angiotensin receptors and signaling mechanisms. Am J Physiol Regul Integr Comp Physiol. 2012; 302 (5): R518-R530
7. Steckelings UM, Paulis L, Namsolleck P, Unger T., AT2 receptor agonists: hypertension and beyond. Curr Opin Nephrol Hypertens. 2012; 21 (2): 142-146
8. Solomon SD, Zile M, Pieske B, et al., The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial. Lancet. 2012; 380 (9851): 1387-1395
9. Vardeny O, Tacheny T, Solomon SD., First-in-class angiotensin receptor neprilysin inhibitor in heart failure. Clin Pharmacol Ther. 2013; 94 (4): 445-448
10. McMurray JJ, Packer M, Desai AS, et al., Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014; 371 (11): 993-1004
11. Du Y, Chandra P, Alshare Q, et al., An open-label, single dose study to investigate the absorption, distribution, metabolism, and elimination of [14C]-LCZ696 and its metabolites in healthy male subjects. AAPS Annual Meeting and Exposition. San Antonio; 2013: 10-14
12. Corp NP., Diovan Prescribing Information. 2014. http://wwwpharmausnovartiscom/cs/wwwpharmausnovartiscom/product/pi/pdf/diovanpdf
13. Waldmeier F, Flesch G, Muller P, et al., Pharmacokinetics, disposition and biotransformation of [14C]-radiolabelled valsartan in healthy male volunteers after a single oral dose. Xenobiotica. 1997; 27 (1): 59-71
14. Bressler R, Bahl JJ., Principles of drug therapy for the elderly patient. Mayo Clin Proceed. 2003; 78 (12): 1564-1577
15. Franconi F, Brunelleschi S, Steardo L, Cuomo V., Gender differences in drug responses. Pharm Res. 2007; 55 (2): 81-95
16. Soldin OP, Mattison DR,. Sex differences in pharmacokinetics and pharmacodynamics. Clin Pharmacokinet. 2009; 48 (3): 143-157
17. Turnheim K., Drug therapy in the elderly. Exp Gerontol. 2004; 39 (11-12): 1731-1738
18. Callow AD., Cardiovascular disease 2005-the global picture. Vascul Pharmacol. 2006; 45 (5): 302-307
19. Conroy RM, Pyorala K, Fitzgerald AP, et al., Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J. 2003; 24 (11): 987-1003
20. Guidance for industry: bioavailability and bioequivalence studies for orally administered drug products-general considerations: US Department of Health and Human Services, FDA; 2003: 1-26
21. Muhlberg W, Platt D., Age-dependent changes of the kidneys: pharmacological implications. Gerontology. 1999; 45 (5): 243-253
22. Prasad P, Mangat S, Choi L, et al., Effect of renal function on the pharmacokinetics of valsartan. Clin Drug Invest. 1997; 13 (4): 207-214
23. Sioufi A, Marfil F, Jaouen A, et al., The effect of age on the pharmacokinetics of valsartan. Biopharm Drug Dispos. 1998; 19 (4): 237-244
24. Le Couteur DG, McLean AJ., The aging liver. Drug clearance and an oxygen diffusion barrier hypothesis. Clin Pharmacokinet. 1998; 34 (5): 359-373
25. Zeeh J, Platt D., The aging liver: structural and functional changes and their consequences for drug treatment in old age. Gerontology. 2002; 48 (3): 121-127
26. Cabaleiro T, Roman M, Ochoa D, et al., Evaluation of the relationship between sex, polymorphisms in CYP2C8 and CYP2C9, and pharmacokinetics of angiotensin receptor blockers. Drug Metab Dispos. 2013; 41 (1): 224-229
27. McMurray JJ, Packer M, Desai AS, et al., Baseline characteristics and treatment of patients in prospective comparison of ARNI with ACEI to determine impact on global mortality and morbidity in heart failure trial (PARADIGM-HF). Eur J Heart Fail. 2014; 16 (7): 817-825